1,720,998 research outputs found
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
Study of biomarkers of response to systemic treatments and identification of new therapeutic targets in bladder and ureter cancers
No full textLe cancer de vessie est responsable de 212 536 décès en 2020 dans le monde. Il est constitué de tumeurs n’infiltrant pas le muscle (TVNIM, à risque de récidives locales), et infiltrant le muscle (TVIM, à risque de disséminations métastatiques et de décès). 95% sont des cancers urothéliaux alors que 5% sont des cancers épidermoïdes. Au niveau moléculaire, ces tumeurs sont caractérisées principalement par des tumeurs luminales (incluant des Luminales-papillaires) ou basales (Ba/Sq). Le traitement en 2022 est principalement basé, pour les stades avancés, sur la chimiothérapie (incluant les anticorps drogues conjugués), l’immunothérapie par inhibiteur de point de contrôle immunitaire (IPI, anticorps anti-PD-1/L1) et les inhibiteurs de FGFR en cas d’altérations génomiques FGFR2/3. Ces traitements ont néanmoins une efficacité modérée.Les objectifs de cette thèse étaient dans les TVIM de rechercher des biomarqueurs de sensibilité ou de résistance aux traitements ainsi que de rechercher de nouvelles pistes thérapeutiques.Concernant la recherche de biomarqueurs de réponse ou de résistance dans les TVIM nous avons pu montrer que :- les structures lymphoïdes tertiaires, mesurées par l’expression du gène CXCL13, sont un biomarqueur prédictif majeur de réponse aux anticorps anti-PD-L1, et sont enrichies dans le type Ba/Sq, (étude réalisée via l’analyse de cohortes publiques comme IMVIGOR210) ;- les cellules plasmatiques semblent également un biomarqueur de réponse aux IPI dans les TVIM métastatiques (conclusion basée sur des résultats préliminaires des données de séquençage de noyaux uniques de la cohorte MATCH-R avant et pendant le traitement par IPI) ;- une combinaison thérapeutique par anti-FGFR (erdafitinib) + anti-EGFR (erlotinib) est efficace dans des PDXs (patient-derived xenografts) mutés pour FGFR3, cette efficacité étant probablement due à une surexpression d’ERBB2-3 et d’EGFR sous inhibiteur de FGFR ;- les tumeurs sarcomatoïdes présentaient une expression/activité plus faible d’EGFR et un switch vers FGFR1, responsable d’une moindre réponse à un inhibiteur d’EGFR par rapport aux autres TVIM Ba/Sq ;Nous avons pu identifier de nouvelles pistes thérapeutiques dans les lignées cellulaires de cancers urothéliaux :- RARy, partenaire de RXRα, cible identifiée dans la base publique de criblage par CRISPR-Cas9 de lignées cellulaires (DepMap). RARy est activé dans les TVIM en particulier dans les sous-types Ba/Sq et Luminales-papillaires, et son inhibition semble intéressante en particulier dans le sous type Ba/Sq.- Le birinapant (XIAP/cIAP1/2 inhibiteur, Smac-mimétique) qui est efficace dans certaines lignées de cancer de vessie selon les données de DepMap. L’efficacité du birinapant a été confirmée in vitro et in vivo au laboratoire dans les lignées UMUC14 et SCaBER, avec comme biomarqueur de sensibilité potentiel l’amplification de BIRC2 ou la surexpression de RIPK1.- FGFR1 qui est une nouvelle piste thérapeutique dans les cancers de vessie de type sarcomatoïde.Bladder cancer is responsible for 212,536 deaths worldwide in 2020. It includes tumors that do not infiltrate the muscle (NMIBC, at risk of local recurrence), and tumors that infiltrate the muscle (MIBC, at risk of metastatic dissemination and death). 95% are urothelial cancers while 5% are squamous cell cancers. At the molecular level, these tumors are characterized mainly by luminal (including luminal-papillary) or basal (Ba/Sq) tumors. Treatment in 2022 is mainly based for advanced stages on chemotherapy (including antibody-drug conjugates), immune checkpoint inhibitor (ICI, anti-PD-1/L1 antibodies) and FGFR inhibitors in case of FGFR2/3 genomic alterations. However, these treatments have a moderate efficacy.The objectives of this thesis were to search for biomarkers of sensitivity or resistance to these treatments and to look for new therapeutic approaches.Concerning the search for biomarkers of response or resistance in MIBC, we were able to show that :- tertiary lymphoid structures, measured by the expression of the CXCL13 gene, are a major predictive biomarker of response to anti-PD-L1 antibodies, and are enriched in the Ba/Sq type, (analysis of public cohorts such as IMVIGOR210);- plasma cells also appear to be a biomarker of response to ICI in metastatic MIBC (conclusion based on preliminary results of single nuclei sequencing data from the MATCH-R cohort before and during ICI treatment);- combination therapy with anti-FGFR (erdafitinib) + anti-EGFR (erlotinib) is effective in FGFR3-mutated PDXs (patient-derived xenografts), probably due to overexpression of ERBB2-3 and EGFR under FGFR inhibitor;- sarcomatoid tumors showed lower EGFR expression/activity and a switch to FGFR1, responsible for a lower response to an EGFR inhibitor compared to other Ba/Sq MIBC.We were able to identify new therapeutic approaches in urothelial cancer cell lines:- RARy, a partner of RXRα, a target identified in the public CRISPR-Cas9 screening cell line database (DepMap). RARy is activated in MIBC particularly in the Ba/Sq and Luminal-papillary subtypes, and its inhibition appears to be of interest particularly in the Ba/Sq subtype.- Birinapant (XIAP/cIAP1/2 inhibitor, Smac-mimetic) which is effective in some urinary cancer lines according to DepMap data. The efficacy of birinapant has been confirmed in vitro and in vivo in UMUC14 and SCaBER cell lines, with BIRC2 amplification or RIPK1 overexpression as potential biomarkers of sensitivity.- FGFR1 which is a new therapeutic lead in sarcomatoid bladder cancer
Author-wise bibliometric analysis based on entropy.
No full textAuthor-wise bibliometric analysis based on entropy.</p
Author Under Sail The Imagination of Jack London, 1893-1902
No full textIn Author Under Sail, Jay Williams offers the first complete literary biography of Jack London as a professional writer engaged in the labor of writing. It examines the authorial imagination in London's work, the use of imagination in both his fiction and nonfiction, and the ways he defined imagination in the creative process in his business dealings with his publishers, editors, and agents. In this first volume of a two-volume biography, Williams traverses the years 1893 to 1902, from London's "Story of a Typhoon" to The People of the Abyss. The Jack London who emerges in the pages of Author Under Sail is a writer whose partnership with publishers, most notably his productive alliance with George Brett of Macmillan, was one of the most formative in American literary history. London pioneered many author models during the heyday of realism and naturalism, blurring the boundaries of these popular genres by focusing on absorption and theatricality and the representation of the seen and unseen. London created an impassioned, sincere, and extremely personal realism unlike that of other American writers of the time. Author Under Sail is a literary tour de force that reveals the full range of London as writer, creative citizen, and entrepreneur at the same time it sheds light on the maverick side of machine-age literature.Intro -- Title Page -- Copyright Page -- Dedication -- Contents -- Acknowledgments -- Introduction -- 1. Spirit Truth -- 2. From Absorption to Theatricality and Back Again -- 3. "I Will Build a New Present" -- 4. Sons as Authors -- 5. Fathers as Publishers -- 6. The Daughter as Author -- 7. Lovers as Authors -- 8. At Sea with the Family -- 9. Yellow News, Yellow Stories -- 10. The Return Home -- Notes -- Bibliography -- Index -- About Jay WilliamsIn Author Under Sail, Jay Williams offers the first complete literary biography of Jack London as a professional writer engaged in the labor of writing. It examines the authorial imagination in London's work, the use of imagination in both his fiction and nonfiction, and the ways he defined imagination in the creative process in his business dealings with his publishers, editors, and agents. In this first volume of a two-volume biography, Williams traverses the years 1893 to 1902, from London's "Story of a Typhoon" to The People of the Abyss. The Jack London who emerges in the pages of Author Under Sail is a writer whose partnership with publishers, most notably his productive alliance with George Brett of Macmillan, was one of the most formative in American literary history. London pioneered many author models during the heyday of realism and naturalism, blurring the boundaries of these popular genres by focusing on absorption and theatricality and the representation of the seen and unseen. London created an impassioned, sincere, and extremely personal realism unlike that of other American writers of the time. Author Under Sail is a literary tour de force that reveals the full range of London as writer, creative citizen, and entrepreneur at the same time it sheds light on the maverick side of machine-age literature.Description based on publisher supplied metadata and other sources.Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, YYYY. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries
- …
